The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension.

[1]  M. Heymans,et al.  Systematic review with meta‐analysis: risk factors for thiopurine‐induced leukopenia in IBD , 2019, Alimentary pharmacology & therapeutics.

[2]  M. Goumans,et al.  Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling , 2019, European Respiratory Journal.

[3]  R. Boellaard,et al.  3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung: A Potential Biomarker for Pulmonary Arterial Hypertension , 2018, Circulation. Cardiovascular imaging.

[4]  Phillip C. Yang,et al.  Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[5]  S. Gräf,et al.  Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension , 2015, Nature Medicine.

[6]  J. V. van Ginkel,et al.  Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.

[7]  N. Voelkel,et al.  Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  S. Archer,et al.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[9]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[10]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.